“PO-41 | Eptinezumab for difficult-to-treat migraine: who responds and who needs more: Alessandro Visentini,1,2,3 Roberta Messina,1,2,3 Ilaria Cetta,1,2,3 Edorardo Ratto,1 Laura Zanandrea,1,3 Federica Genovese,1,2,3 Irene Chinali,1 Bruno Colombo,1 Massimo Filippi1,2,3 | 1Neurology Unit and 2Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 3Vita-Salute San Raffaele University, Milan, Italy” (2025) Confinia Cephalalgica, 35(S1). doi:10.4081/cc.2025.15863.